|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Myriad Genetics, Inc. (MYGN) Presents Variant of Uncertain Significance Rates at European Human Genetics Conference 2012
6/25/2012 10:08:30 AM
ZURICH, Switzerland--(BUSINESS WIRE)--Myriad Genetics GmbH announced today that a presentation entitled “Current Variant of Uncertain Significance Rates in BRCA 1/2 and Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) Testing,” was presented today at the European Human Genetics Conference in Nurnberg, Germany. The study highlights Myriad’s best-in-class variant classification process and variant of uncertain significance rate. Researchers analyzed the variant of uncertain significance rate for the BRACAnalysis® test (BRCA 1 and BRCA 2 genes) test as well as the COLARIS® test (MLH1, MSH2, MSH6, PMS2 and EPCAM genes). From 2002 to 2012, Myriad’s overall uncertain variant rate decreased due to significant investments made in the development and application of improved processes and statistical techniques and the implementation of a targeted program designed to gather data on family members. Across all ancestries, the BRCA 1 and BRCA 2 variant of uncertain significance rate declined from 12.8% to 2.9%. Further, the variant of uncertain significance rate for Lynch syndrome, a test analyzing the MLH1, MSH2, MSH6, and EPCAM genes, declined to 6.6% in 2012. The variant of uncertain significance for PMS2 gene test, also for Lynch Syndrome, was 4.0%.
|
|
|
|
|
|
|
|
|
|
|